ライフサイエンスコーパス: dapsone

1 ee antibiotics: rifampicin, clofazimine, and dapsone.

2 mbination of antihistamines, colchicine, and dapsone.

3 ng a combination of glucocorticosteroids and dapsone.

4 vitro, and it possessed activity similar to dapsone.

5 one and from 3.2 to 3.8 A in the presence of dapsone.

6 se in resistance to S/P or to chlorproguanil-dapsone.

7 tient is placed on a gluten-free diet and/or dapsone.

8 reased (decrease in K(S)) by the presence of dapsone.

9 en in the presence and absence of 100 microM dapsone.

10 ersensitivity caused by sulfamethoxazole and dapsone.

11 ing resistance to sulfamethoxazole (SMX) and dapsone.

12 roxylation and S-naproxen O-demethylation by dapsone.

13 ion of a clinically important drug molecule, Dapsone.

14 rson-years; relative risk for atovaquone vs. dapsone, 0.85; 95 percent confidence interval, 0.67 to 1

15 ne (-6.7%, -45.9 to 22.0) nor chlorproguanil-dapsone (10.8%, -24.6 to 36.1) had a protective effect.

16 y atovaquone (1500-mg suspension) with daily dapsone (100 mg) for the prevention of P. carinii pneumo

17 smission sites), chlorproguanil (15 mg) plus dapsone (18.75 mg; n=317 and 285), mefloquine (125 mg; n

18 in distance from the heme in the presence of dapsone, 3.50 A, as compared to the absence of dapsone,

19 od is based on the diazotization reaction of dapsone (4,4'-diamino-diphenyl sulphone, DAP) and (napht

20 ials of antimalarial preparations containing dapsone (4,4'-diaminodiphenylsulfone; 2.5 mg/kg once dai

21 psone, 3.50 A, as compared to the absence of dapsone, 4.41 A.

22 nts was 3.78 for atovaquone as compared with dapsone (95 percent confidence interval, 2.37 to 6.01; P

23 It has been demonstrated previously that dapsone activates the CYP2C9-catalyzed oxidation of a nu

24 ion of phenanthrene metabolism by CYP3A4 and dapsone activation of flurbiprofen and naproxen metaboli

25 rther identified a pivotal role of Phe476 in dapsone activation.

26 g peroxidases and catalase) and 42 +/- 9% by dapsone (an inhibitor of lactoperoxidase).

27 Treating diabetic rats with dapsone, an agent known to inhibit neutrophil function,

28 ogic problems associated with drugs, such as dapsone and azathioprine, respectively.

29 Measures of dapsone and flurbiprofen metabolism were elevated throug

30 e ranged from 4.2 to 4.5 A in the absence of dapsone and from 3.2 to 3.8 A in the presence of dapsone

31 More infants died in the chlorproguanil-dapsone and mefloquine groups (18 and 15, respectively)

32 A treatment program including dapsone and other drugs completely resolved the oral les

33 p=0.05 for difference between chlorproguanil-dapsone and placebo).

34 the closed loop 1; (ii) the distribution of dapsone and sulfonamide resistance mutations; (iii) the

35 -containing compounds such as the antibiotic dapsone and the antidepressant vortioxetine.

36 d by gluten-free diet (with poor adherence), dapsone, and conventional immune-suppressing agents resp

37 In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed f

38 second-line therapies, including atovaquone, dapsone, and pentamide.

39 When M. leprae was exposed to rifampicin, dapsone, and Q203 for 24 and 48 h, followed by TM4::GeNL

40 m-dependent toxicity of sulfamethoxazole and dapsone, and subsequent incubation of normal human epide

41 aromatic interactions between the substrate, dapsone, and the phenyl rings of Phe114 and Phe476 withi

42 rimethoprim-sulfamethoxazole, atovaquone and dapsone are similarly effective for the prevention of P.

43 involving 872 participants who had received dapsone as part of multidrug therapy for leprosy (39 par

44 lticenter trials highlighted doxycycline and dapsone as valuable medications in the treatment of bull

45 to 6.01; P<0.001); among those not receiving dapsone at base line, it was 0.42 (95 percent confidence

46 Among the 546 patients who were receiving dapsone at base line, the relative risk of discontinuati

47 However, among those not receiving dapsone, atovaquone is better tolerated and may be the p

48 described in detail were first treated with dapsone, but only 1 responded to this treatment.

49 usly in the active site with the presence of dapsone causing flurbiprofen to be oriented more closely

50 assess the safety profile of chlorproguanil-dapsone (CD), and to compare the safety and efficacy of

51 e spread of drug-resistant strains; however, dapsone (DDS) resistance continues to be reported.

52 Today, dapsone (DDS) resistance has led to fear of leprosy in m

53 HLA-B*13:01 is associated with dapsone (DDS)-induced hypersensitivity, and it has been

54 d by DDS and its nitroso metabolite (nitroso dapsone [DDS-NO]).

55 In contrast to flurbiprofen and naproxen, dapsone did not activate the 4'-hydroxylation of diclofe

56 sulfadoxine-pyrimethamine or chlorproguanil-dapsone did.

57 ulfadoxine-pyrimethamine, and chlorproguanil-dapsone for the treatment of P vivax malaria was conduct

58 n-years), as compared with 135 of 521 in the dapsone group (18.4 cases per 100 person-years; relative

59 of 272 patients (9.9%) in the chlorproguanil-dapsone group.

60 Dapsone hydroxylamine also caused covalent adduct format

61 ts of sulfamethoxazole hydroxylamine but not dapsone hydroxylamine.

62 01 was confirmed to be a risk factor for the dapsone hypersensitivity syndrome (odds ratio, 20.53; P=

63 loci, was significantly associated with the dapsone hypersensitivity syndrome among patients with le

64 1 was associated with the development of the dapsone hypersensitivity syndrome among patients with le

65 Ps in an additional 31 participants with the dapsone hypersensitivity syndrome and 1089 controls and

66 dependent series of 37 participants with the dapsone hypersensitivity syndrome and 201 controls.

67 herapy for leprosy (39 participants with the dapsone hypersensitivity syndrome and 833 controls), usi

68 a specificity of 85.7% as a predictor of the dapsone hypersensitivity syndrome, and its absence was a

69 The dapsone hypersensitivity syndrome, which is associated w

70 sts are available to predict the risk of the dapsone hypersensitivity syndrome.

71 to be widely used for leprosy treatment was dapsone in the 1950s, which had to be taken over several

72 he relative orientations of flurbiprofen and dapsone in the active site of CYP2C9.

73 on of incubations of recombinant CYP2C9 with dapsone increased the catalytic efficiency of flurbiprof

74 Dapsone is used in the treatment of infections and infla

75 systemic therapies, such as corticosteroids, dapsone, isotretinoin, and/or antibiotics.

76 o the heme iron of CYP2C9 in the presence of dapsone may play a role in activation.

77 sm by CYPs 2B6, 2C8, 2C9, and 3A5 as well as dapsone metabolism by CYP2C9.

78 enytoin (CYP-2C19), chlorzoxazone (CYP-2E1), dapsone (multiple CYP enzymes), and flurbiprofen (CYP-2C

79 s well as corticosteroids, cyclophosphamide, dapsone, mycophenolate mofetil, plasmapheresis, colchici

80 14), trimethoprim-sulfamethoxazole (n = 11), dapsone (n = 4), allopurinol (n = 10), and other drugs (

81 ed with five phytochemicals independently as dapsone-phytochemical conjugates (DPCs) based on azo-cou

82 ulcer margin; topical cromolyn sodium; oral dapsone, prednisone, cyclosporine, mycophenolate mofetil

83 Our results support the continuation of dapsone prophylaxis among patients who are already recei

84 Dapsone protons were less affected, being 4.40 A from th

85 ied primary drug resistance in 4 cases and a dapsone-resistant cluster caused by the same strain.

86 Of these, 2 had dapsone-resistant Mycobacterium leprae and 1 of these pa

87 ty (pamaquine, sitamaquine, tafenoquine, and dapsone) resulted in loss of G6PD-deficient huRBCs compa

88 ydroxylation is activated by the presence of dapsone resulting in reduction of the K(m) for flurbipro

89 DRDRs) of folP1, rpoB, and gyrA, targets for dapsone, rifampin, and fluoroquinolones, real-time PCR-H

90 Within 1 month after initiating dapsone therapy and increasing the dosage of prednisone,

91 ratinocytes metabolized sulfamethoxazole and dapsone to N-4-hydroxylamine and N-acetyl derivatives in

92 s of the prototypical CYP2C9 heteroactivator dapsone to validate a simple docking method that can be

93 reatment failure but not with chlorproguanil-dapsone treatment failure.

94 sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment for uncomplicated P. falciparum malari

95 methamine-sulfadoxine but not chlorproguanil-dapsone treatment, showing that a combination of these t

96 le typically managed by gluten-free diet and dapsone, treatment of DH refractory to standard treatmen

97 ced, and the relationship between TMP-SMX or dapsone use and gene mutations was analyzed.

98 pyrimethamine-sulfadoxine or chlorproguanil-dapsone was analyzed for variants of the genes coding fo

99 Chlorproguanil-dapsone was less effective than sulfadoxine-pyrimethamin

100 Multidrug resistance to rifampicin and dapsone was observed in 8 relapses and 4 new cases.

101 Resistance to dapsone was present in 2 relapses and 1 new case.

102 ration of a gluten-free diet with or without dapsone were observed.

103 eatment, a combination therapy consisting of dapsone with cimetidine and vitamin E to enhance drug ef